Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 50%
The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.
CNBC
Published by CurrentWire · First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from CNBC.
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How coverage developed
First report from CNBC
Story updateHeadline updated
How CurrentWire compiled this story
CNBC (www.cnbc.com), a Tier B publisher, filed this report on . CurrentWire published this page on .
Signal breakdown
CurrentWire ranked this story 59.7 of 100 in the snapshot this page was rendered from.
- Freshness
- 33.7 of 35
- Source authority
- 14 of 20
- Coverage breadth
- 4 of 20
- Geographic relevance
- 3.5 of 10
- Story prominence
- 4.5 of 10
- Velocity
- 0 of 5
Strongest signal: freshness, 33.7 of 35. How each signal is calculated.
Filed under Health · International · News.
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.